These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19236131)

  • 1. Contradictory actions on off-label use of prescription drugs? The FDA and CMS versus the U.S. Justice Department.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2009 Mar; 15(2):161-5. PubMed ID: 19236131
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 3. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
    Seetasith A; Holdford D; Shah A; Patterson J
    Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicians' liability for off-label prescriptions.
    Riley JB; Basilius PA
    Nephrol News Issues; 2007 Jun; 21(7):43-4, 46-7. PubMed ID: 17623984
    [No Abstract]   [Full Text] [Related]  

  • 5. Take this medicine: the legality of prescription incentive schemes.
    Fanning J; Glover-Thomas N
    Med Law Rev; 2010; 18(3):417-26. PubMed ID: 20739438
    [No Abstract]   [Full Text] [Related]  

  • 6. Kept in the dark: Scotland rejects "sunshine" legislation.
    Ross JS
    BMJ; 2019 Mar; 364():l1379. PubMed ID: 30926587
    [No Abstract]   [Full Text] [Related]  

  • 7. Making Sense of MACRA, Part 2: Value-Based Payment and Your Future.
    Mullins A
    Fam Pract Manag; 2017; 24(1):12-15. PubMed ID: 28075077
    [No Abstract]   [Full Text] [Related]  

  • 8. CMS asserts broad authority over physician prescribing practices.
    Saner RJ; Rathmell JP
    Pain Med; 2015 Mar; 16(3):421-4. PubMed ID: 25786650
    [No Abstract]   [Full Text] [Related]  

  • 9. The Law and Practice of Off-Label Prescribing and Physician Promotion.
    Syed SA; Dixson BA; Constantino E; Regan J
    J Am Acad Psychiatry Law; 2021 Mar; 49(1):53-59. PubMed ID: 33234538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical Marketing in the United States, 1997-2016.
    Schwartz LM; Woloshin S
    JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telehealth for Substance-Using Populations in the Age of Coronavirus Disease 2019: Recommendations to Enhance Adoption.
    Lin LA; Fernandez AC; Bonar EE
    JAMA Psychiatry; 2020 Dec; 77(12):1209-1210. PubMed ID: 32609317
    [No Abstract]   [Full Text] [Related]  

  • 12. Is the DEA's new "prescription series" regulation balanced?
    Gilson AM; Joranson DE
    J Pain Palliat Care Pharmacother; 2008; 22(3):218-20. PubMed ID: 19042852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stopping the practice of authorized generics: Mylan's effort to close the gaping black hole in the Hatch-Waxman act.
    Porter B
    J Contemp Health Law Policy; 2005; 22(1):177-209. PubMed ID: 16680993
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Legislative/Legal History of Prescription Drug Advertising and Promotion Regulation.
    Li S; Gibbs I
    J Pharm Pharm Sci; 2021; 24():381-389. PubMed ID: 34314671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should We Fear the Unintended Consequences of MACRA?
    Adler KG
    Fam Pract Manag; 2017; 24(1):4. PubMed ID: 28075074
    [No Abstract]   [Full Text] [Related]  

  • 17. To risk prescribing this drug, or not to risk: that is the question.
    Bushardt R; Jones KW
    JAAPA; 2009 Mar; 22(3):10. PubMed ID: 19354107
    [No Abstract]   [Full Text] [Related]  

  • 18. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A; Carome MA
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract]   [Full Text] [Related]  

  • 19. Has the multiple prescription debacle truly been resolved?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2008; 22(2):99-100. PubMed ID: 19042836
    [No Abstract]   [Full Text] [Related]  

  • 20. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.